Cytoreductive Surgery and HIPEC for Recurrent Fibrolamellar Hepatocellular Carcinoma with Peritoneal Carcinomatosis

  • D. Kyziridis
  • A. Kalakonas
  • K. Zarambouka
  • C. Hristakis
  • Antonios-Apostolos K. TentesEmail author
Case Report


Fibrolamellar hepatocellular carcinoma (FHCC) is a rare type of hepatocellular carcinoma (HCC), accounting 1–9% of primary liver tumors [1]. The diagnosis is based on the elevation of the serum vitamin B12 level [2, 3]. The recurrence rate is high even after curative surgery and the response to systemic chemotherapy is very poor. The purpose of the study is the presentation of a patient with FHCC that underwent CRS+HIPEC after sequential local-regional recurrences in a 10-year period.

Case Report

A 34-year-old female patient complaining for abdominal discomfort, sensation of gastric fullness, and epigastric tenderness presented with a liver tumor of the left lobe, 11 years ago. The abdominal magnetic resonance (MRI) showed the presence of a large tumor of the left liver lobe. The hematological-biochemical examinations and tumor markers were normal despite an excessive elevation of serum vitamin B12(> 2000 pg/mL; normal range 200–900 pg/mL). The patient underwent...


Author Contributions

D. Kyziridis: writer of the surgical details

A. Kalakonas: supervisor

K. Zarambouka: writer of the pathological details

C. Hristakis: supervisor

A. A. Tentes: supervisor of the manuscript

Compliance with Ethical Standards

The ethical committee of the hospital approved the treatment and the patient gave informed consent.

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Simon EP, Freije CA, Farber BA, Lalazar G, Darcy DG, Honeyman JN, et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. PNAS. 2015;112:E5916–25.CrossRefGoogle Scholar
  2. 2.
    Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Col Surg. 2012;215:820–30.CrossRefGoogle Scholar
  3. 3.
    Cui LH, Quan ZY, Piao JM, Zhang TT, Jiang MH, Shin MH, et al. Plasma folate and vitamin B12 levels in patients with hepatocellular carcinoma. Jpn J Clin Oncol. 2004;34:346–51.CrossRefGoogle Scholar
  4. 4.
    Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancers with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–32.CrossRefGoogle Scholar
  5. 5.
    Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91:168–86.Google Scholar
  6. 6.
    El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39:798–803.CrossRefGoogle Scholar
  7. 7.
    Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D'Angelica M, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331–8.CrossRefGoogle Scholar
  8. 8.
    Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980;46:372–9.CrossRefGoogle Scholar
  9. 9.
    Lafaro KJ, Pawlik TM. Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma. 2015;2:151–7.Google Scholar
  10. 10.
    Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013;85:197–203.CrossRefGoogle Scholar
  11. 11.
    Trevisani F, D'Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazziotti A, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Cancer. 1995;75:2220–32.CrossRefGoogle Scholar
  12. 12.
    Wahab MA, El Hanafy E, El Nakeeb A, Ali MA. Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period). World J Gastrointest Surg. 2017;9:61–7.CrossRefGoogle Scholar
  13. 13.
    Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005;18:1417–23.CrossRefGoogle Scholar
  14. 14.
    Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Balaraman K, et al. Bile duct thrombi in hepatocellular carcinoma: is aggressive surgery worthwhile? HPB. 2015;17:508–13.CrossRefGoogle Scholar
  15. 15.
    Groeschl RT, Miura JT, Wong RK, Bloomston M, Lidsky ML, Clary BM, et al. Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. J Surg Oncol. 2014;110:412–5.CrossRefGoogle Scholar
  16. 16.
    Wojcicki M, Lubikowski J, Post M, Chmurowicz T, Wiechowska-Kozlowska A, Krawczyk M. Aggressive surgical management of recurrent lymph node and pancreatic head metastases of resected fibrolamellar hepatocellular carcinoma: a case report. JOP. 2012;13:529–32.Google Scholar
  17. 17.
    Ringe B, Wittekind C, Weimann A, Tusch G, Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992;175:299–305.Google Scholar
  18. 18.
    Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol. 2016;14:151.CrossRefGoogle Scholar
  19. 19.
    Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19:784–94.CrossRefGoogle Scholar
  20. 20.
    Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21:421–7.CrossRefGoogle Scholar
  21. 21.
    Braune C1, Fangmann J, Scheumann GF, Klempnauer J. Multiorgan resection in combination with intraoperative, hyperthermic chemotherapy in recurrent fibrolamellar hepatocellular carcinoma. An individual therapeutic concept for a 21-year-old patient. Zentralbl Chir. 2001;126:318–21.CrossRefGoogle Scholar
  22. 22.
    Mehta S, Schwartz L, Spiliotis J, Hsieh M-C, Akaishi EH, Goere D, et al. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? EJSO. 2018.
  23. 23.
    Amblard I, Mercier F, Bartlett DL, Ahrendt SA, Lee KW, Zeh HJ, et al. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: a multi-institutional cohort from PSOGI and BIG RENAPE groups. EJSO. 2018;44:1378–83. Scholar
  24. 24.
    Sardi A, Jimenez W, Nieroda C, Sittig M, Shankar S, Gushchin V. Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21:908–14.CrossRefGoogle Scholar
  25. 25.
    Bijelic L, Sugarbaker PH, Stuart OA. Hyperthermic intraperitoneal chemotherapy with Melphalan: a summary of clinical and pharmacological data in 34 patients. Gastroenterol Res Pract. 2012;2012:5.827534.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Surgical OncologyEuromedica Kyanous StavrosThessalonikiGreece
  2. 2.Laboratory of PathologyAristotelian University of ThessalonikiThessalonikiGreece

Personalised recommendations